Why the study?
Liposomal doxorubicin hypersensitivity poses a critical barrier to treatment in breast cancer, but effective predictive biomarkers are lacking.
What are the plasma metabolic changes associated with hypersensitivity to liposomal doxorubicin in breast cancer patients?
What are the plasma metabolic changes associated with hypersensitivity to liposomal doxorubicin in breast cancer patients?
Metabolomic profiling identified cytosine, 5,6-DHET, and l-histidine as potential highly accurate predictive biomarkers for liposomal doxorubicin-induced hypersensitivity in breast cancer patients.
Answers are grounded in this paper and cite their sources.
May support risk stratification for liposomal doxorubicin; hypothesis-generating and requires prospective validation.
BACKGROUND: Liposomal doxorubicin hypersensitivity significantly affects breast cancer patients, with widely varying incidence rates (9 % to 46 %). Despite its efficacy, this condition poses a critical barrier to treatment due to the need for precise patient management and the absence of effective predictive biomarkers. This hypothesis-generating, exploratory study aimed to characterize plasma metabolic changes associated with hypersensitivity to liposomal doxorubicin in breast cancer patients, with the goal of identifying potential predictive biomarkers for future validation. METHODS: A retrospective metabolomic study was conducted on plasma samples from breast cancer patients treated with liposomal doxorubicin. Untargeted metabolomics was analyzed using LC-MS. Statistical methods, including Principal Component Analysis and Partial Least Squares Discriminant Analysis, were employed to identify significant metabolic changes, with a variable importance in projection score ≥1.0 and a p ≤ 0.05 as criteria for significance. RESULTS: Twelve breast cancer patients were included in this study (7 with immediate hypersensitivity). Differential metabolites revealed by the analysis included significant downregulation of 5,6-Dihydroxyeicosatrienoic acid (5,6-DHET) and kynurenic acid, along with marked upregulation of l-histidine. Pathway enrichment analysis highlighted dysregulation of key metabolic pathways, including the metabolism of phenylalanine, tyrosine, and β-alanine metabolism. Notably, the receiver operating characteristic curves demonstrated high diagnostic accuracy for several metabolites, including cytosine (AUC = 1.00), 5,6-DHET (AUC = 0.97), and l-histidine (AUC = 0.94), in predicting hypersensitivity. CONCLUSION: Liposomal doxorubicin-induced hypersensitivity involves a metabolic network characterized by impaired anti-inflammatory responses (5,6-DHET/kynurenic acid depletion), histamine pathway activation (L-histidine accumulation), and aromatic amino acid dysregulation. These findings establish a novel biomarker framework for predicting hypersensitivity risk and provide mechanistic insights for targeted interventions.
No takes yet. Share an insight, caveat, or question.
Su et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: